"Designing Growth Strategies is in our DNA"
The global intravenous immunoglobulin (IVIG) market size was valued at USD 9,787.6 Million in 2017 and is projected to reach USD 15,789.1 Million by 2025 exhibiting a CAGR of 6.2% in the forecast period (2018-2025).
Immunoglobulins are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction.
Intravenous immunoglobulins are the immunoglobulins that are administered through the intravenous route. Intravenous immunoglobulins are the most common route of administration because most of the patients receiving immunoglobulins are in the hospital and clinical settings. This, coupled with the proven efficiency of the immunoglobulins as an effective treatment option for a number of immune diseases and the lack of training for homecare settings is also positively driving the Intravenous Immunoglobulin market growth.
Request a Free sample to learn more about this report.
Some of the other factors which are also contributing to the growth of the Market is its dominance in the both the developed and the developing markets. The ongoing R&D by major market players for the introduction of new and advanced intravenous immunoglobulins is expected to drive the Market growth in developed as well as emerging countries, during the forecast period 2018-2025.
"Increasing adoption of intravenous immunoglobulins as the most common treatment for primary immunodeficiency and dependency on immunoglobulin administration in hospital settings, is driving the market"
The adoption of intravenous immunoglobulin therapy as the first line of treatment for the primary immunodeficiency and other rare immunological and neurological diseases, is one of the most prominent leading to factors that are responsible for the intravenous immunoglobulin market growth in 2017. Primary Immunodeficiency (PI) segment is estimated to have the largest market share among the indication segment.
The Primary Immunodeficiency (PI) segment accounted for a market share of 28.6% in 2017 and is expected to increase during the forecast period. Increasing focus towards the diagnosis of primary immunodeficiency and the subsequent treatment based on the individual case and training of the patient, in most cases the patient is not adept in self-administration, is also driving the primary immunodeficiency segment.
The chronic inflammatory demyelinating polyneuropathy (CIDP) segment is estimated to grow at a slower CAGR during the forecast period. This is attributed to the comparatively lower prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP). Currently, there is an existing dominance of the primary immunodeficiency (PI) as the indication for which intravenous immunoglobulin is the most prescribed for and this is expected to contribute to the growth of the market at higher CAGR during the forecast period.
To know how our report can help streamline your business, Speak to Analyst
On the basis of indication, the intravenous immunoglobulin market segments include primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN), and others. The primary immunodeficiency (PI) segment accounted for 28.6% share of the global Market in 2017. On the basis of form, the global immunoglobulins market segments include liquid, and lyophilized. On the basis of end user, the market segments include hospitals, clinics, and homecare.
"An Increase In The Number Of Immunodeficiences Diagnoses Due To Greater Awareness, along with Increasing Adoption of Immunoglobulins Expected to Result in the Highest CAGR in the Asia Pacific"
The IVIG market in North America was valued at USD 5,587.4 Mn in 2017 and is anticipated to account for a dominant share in the Market during the forecast period. The primary driving factor for the significant and strong growth of the industry is the fact that it is the first line of treatment for a number of critical immune disorders. With the increase in contributing factors of such as the increasing number of patients and the efficiency of the intravenous immunoglobulins as treatment option, is expected to give rise to a significant demand for immunoglobulins. In developed countries, the adoption of advanced intravenous immunoglobulins is growing alongside the increasing number of indications that are approved. India and China in the Asia Pacific region are experiencing growth in the immunoglobulins due to increased diagnosis of primary immunodefiencies in the population. In terms of the dominance of indication, primary immunodeficiency is the most dominating indication in these developing regions. However, in countries like Japan, there is increased adoption and expenditure towards advanced immunoglobulins and Japan holds significant revenue shares in these advanced immunoglobulins. In Latin America and Middle East & Africa, the intravenous immunoglobulins will be popular due to the lack of self-administration of immunoglobulins in these regions.
North America Intravenous Immunoglobulins Market, 2017
To get more information on the regional analysis of this market, Request a Free sample
"Key market players such as Grifols S.A., CSL Behring and Shire (Takeda Pharmaceutical Company Limited) are anticipated to be the leading players in global Market"
Grifols, S.A., emerged as the leading player with the highest intravenous immunoglobulin market share in 2017, as the company has a number of product offerings in the across a wide range of indications and it is the commonly used route of administration, and these product offerings dominate a substantial portion of market share. The company accounts for the highest market revenue from regions such as North America and Europe. In addition, other market players are also getting product approvals such as Shire (Takeda Pharmaceutical Company Limited). The company received regulatory approvals for the immunoglobulin product offering of CUVITRU. Other players operating in the global market are CSL Behring, Grifols, S.A., Kedrion S.p.A, Octapharma, Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., LFB SA and Shanghai RAAS Blood Products Co., Ltd.
Immunoglobulins, also referred to as antibodies, are the glycoprotein molecules manufactured by the plasma or the white blood cells. Immunoglobulins form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. In certain individuals, immunoglobulins have to be administered for the treatment and management of diseases such as primary immunodeficiency (PI). Intravenous immunoglobulins are the most popular form of immunoglobulins, due to the no requirement of self-administration and the easy administration in hospital and clinic settings.
The intravenous immunoglobulin market report provides qualitative and quantitative insights on industry trends and detailed analysis of market size & growth rate for all possible segments in the market. The market segments include indication, form, and end user. On the basis of indication, the market is categorized into (primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN) and others).
An Infographic Representation of Intravenous Immunoglobulins Market
To get information on various segments, share your queries with us
On the basis of form, the market can be segmented into liquid and lyophilized. On the basis of end user, the market can be segmented into hospitals, clinics and homecare. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.
Along with this, the report analysis comprises of market dynamics and competitive landscape. Additionally, the report offers insights on the pipeline analysis, overview of regulatory scenario by key regions, key industry developments, number of primary immunodeficiency (PI) patients by key countries and reimbursement scenario.
· Primary Immunodeficiency
· Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
· Guillain-Barré Syndrome (GBS)
· Immune Thrombocytopenic Purpura (ITP)
· Multifocal Motor Neuropathy (MMN)
By End User
· North America (the U.S., and Canada)
· Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
· Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
· Latin America (Brazil, Mexico, and Rest of Latin America
· Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)
Fortune Business Insights says that the Intravenous Immunoglobulins Market was valued at US$ 9,787.6 Mn in 2017 and is projected to reach US$ 15,789.1 Mn by 2025.
In 2017, the Intravenous Immunoglobulins Market was valued at US$ 9,787.6 Mn.
Growing at a CAGR of 6.2%, the Intravenous Immunoglobulins Market will exhibit steady growth in the forecast period (2018-2025)
Primary Immunodeficiency segment is expected to be the leading segment in Intravenous Immunoglobulins Market during the forecast period.
Increasing adoption of intravenous immunoglobulins due to superior treatment outcomes is the key driving factor of the Intravenous Immunoglobulins Market.
Grifols S.A., CSL Behring and Shire (Takeda Pharmaceutical Company Limited) are the leading market players in Intravenous Immunoglobulins Market.
North America is expected to hold the highest market share in the Intravenous Immunoglobulins Market.
Growing dependency on immunoglobulin administration in hospital settings is one of the trends of Intravenous Immunoglobulins Market.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry